Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
Study Details
Study Description
Brief Summary
This is a Phase II/III vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate nonexudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either topical 1% MC-1101 or a vehicle control over 2 years. The study design will assess the efficacy, safety, and tolerability of MC-1101 for these patients.
An analysis of the primary and secondary endpoints will be conducted when all subjects have completed 12, 18 and 24 months.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2/Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: MC-1101 1% Ophthalmic Solution
|
Drug: MC-1101
1% Ophthalmic Solution TID
|
Placebo Comparator: Vehicle control
|
Drug: MC-1101 Vehicle
Ophthalmic solution, TID
|
Outcome Measures
Primary Outcome Measures
- Visual Function [12 months]
Primary efficacy assessment will be a comparison between groups of the change in visual function at 12 months with additional analyses at 18 and 24 months.
Secondary Outcome Measures
- Safety and Tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia) [24 months]
Evaluate the safety and tolerability (incidence and severity of adverse events, ocular irritability,and ocular hyperemia) of MC-1101 compared to vehicle control at each study visit following treatment for 2 years
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Males and females age ≥ 50 years and ≤ 85 years;
-
Females must be at least 1 year postmenopausal (after last menstrual period) or sterilized;
-
Better than 20/80 ETDRS best corrected visual acuity;
-
Mild to moderate nonexudative AMD (AMD steps 3 through 8 on Age-Related Eye Disease Study (AREDS) Report No. 17 grading scale);
-
Willing to sign informed consent, comply with study protocol requirements, and undergo up to 2.5 hours of testing at each visit;
Exclusion Criteria:
-
Past or current exudative AMD or any geographic atrophy (on fundus autofluorescence) in study eye;
-
Past or current other retinal or choroidal vasculopathy in study eye (e.g. pigment epithelial detachment, polypoidal choroidal vasculopathy, central serous retinopathy, retinal vein occlusion, sickle cell retinopathy);
-
Uncontrolled hypertension (≥ 150 systolic or ≥95 diastolic);
-
Diabetes mellitus;
-
Glaucoma;
-
Lens opacity ≥ grade 3 ARLNS on standard photographs;
-
Unable to complete biophysical testing;
-
Unable to give informed consent;
-
Dilated pupil diameter less than 6 millimeters;
-
Subjects with a history of a hypersensitivity reaction to the study drug or to any agent used in the components of the study assessment;
-
Use of topical ocular medications (other than artificial tear products);
-
Anticipated extra- or intraocular intervention during the study period;
-
High myopia (refractive error spherical equivalent ≥ -6 diopters);
-
Optic neuropathy;
-
Neurological conditions that can impair vision (e.g. Parkinson's disease, multiple sclerosis, Alzheimer's disease);
-
Liver disease (e.g. cirrhosis, hepatitis);
-
History of GI surgery (e.g. bariatric surgery);
-
Unwilling or unable to take an AREDS formula vitamin (without beta-carotene/vitamin A);
-
Current or past use of chloroquine, hydroxychloroquine, chlorpromazine, thioridazine, quinine sulfate, clofazimine, cisplatin, carmustine (BCNU), or deferoxamine;
-
Tobacco smoking (currently or within past 5 years);
-
Contact lens wearers (not prepared to discontinue lens use);
-
Ophthalmic surgery of any kind within 3 months prior to screening visit;
-
Participation in any interventional clinical study requiring IRB approval within 3 months of enrollment;
-
Currently being treated for cancer or any disease likely to adversely affect participation in a 2 year study;
-
Known to have AIDS/HIV
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Michigan | Ann Arbor | Michigan | United States | 48105 |
Sponsors and Collaborators
- MacuCLEAR, Inc.
Investigators
- Principal Investigator: Grant M Comer, MD, University of Michigan
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MacuCLEAR MC-1101-001